"Lutetium-177 vipivotide tetraxetan, also known as 177Lu-PSMA-617 or its trade name Pluvicto (Novartis, USA), is a radioligand theranostic (i.e., both therapeutic and diagnostic) agent approved for the treatment of adult patients with treatment-resistant, advanced metastatic prostate cancer. The compound binds to cancer cells that express prostate-specific membrane antigen (PSMA), a biomarker associated with poor prognosis, and delivers beta-emitting radiation from lutetium 177, resulting in DNA damage and subsequent tumour cell death. Its clinical efficacy has been demonstrated in multiple prospective trials, including VISION and PSMAfore 1,6."
"Pre-treatment PET scan is performed using a PSMA-linked agent. 68Ga PSMA-11 (trade name Illuccix) was utilised in the VISION trial. Additional PSMA diagnostic agents include 18F piflufolastat (trade name Pylarify), 68Ga gozetotide (trade name Locametz), and 18F Flotufolastat (trade name Posluma). Patient selection requires demonstration of PSMA expression using approved PET imaging agents."
"Pre-treatment PET scan is performed using a PSMA-linked agent. 68Ga PSMA-11 (trade name Illuccix) was utilised in the VISION trial. Additional PSMA diagnostic agents include 18F piflufolastat (trade name Pylarify), 68Ga gozetotide (trade name Locametz), and 18F Flotufolastat (trade name Posluma). Patient selection requires demonstration of PSMA expression using approved PET imaging agents."
"Pre-treatment PET scan is performed using a PSMA-linked agent. 68Ga PSMA-11 (trade name Illuccix) was utilised in the VISION trial. Additional PSMA diagnostic agents include 18F piflufolastat (trade name Pylarify), 68Ga gozetotide (trade name Locametz), and 18F Flotufolastat (trade name Posluma). Patient selection requires demonstration of PSMA expression using approved PET imaging agents."
"Pre-treatment PET scan is performed using a PSMA-linked agent. 68Ga PSMA-11 (trade name Illuccix) was utilised in the VISION trial. Additional PSMA diagnostic agents include 18F piflufolastat (trade name Pylarify), 68Ga gozetotide (trade name Locametz), and 18F Flotufolastat (trade name Posluma). Patient selection requires demonstration of PSMA expression using approved PET imaging agents."
"The VISION trial was the landmark phase III international trial that compared outcomes in 831 patients treated with 177Lu-PSMA-617 plus standard of care treatment versus standard of care treatment alone1. It found that median survival increased from 11.3 to 15.3 months with 177Lu-PSMA-617. Progression-free survival was an average of 8.7 months versus 3.4 months with standard of care therapy alone."
"The VISION trial was the landmark phase III international trial that compared outcomes in 831 patients treated with 177Lu-PSMA-617 plus standard of care treatment versus standard of care treatment alone1. It found that median survival increased from 11.3 to 15.3 months with 177Lu-PSMA-617. Progression-free survival was an average of 8.7 months versus 3.4 months with standard of care therapy alone."
"Lutetium-177 vipivotide tetraxetan, also known as 177Lu-PSMA-617 or its trade name Pluvicto (Novartis, USA), is a radioligand theranostic (i.e., both therapeutic and diagnostic) agent approved for the treatment of adult patients with treatment-resistant, advanced metastatic prostate cancer. The compound binds to cancer cells that express prostate-specific membrane antigen (PSMA), a biomarker associated with poor prognosis, and delivers beta-emitting radiation from lutetium 177, resulting in DNA damage and subsequent tumour cell death. Its clinical efficacy has been demonstrated in multiple prospective trials, including VISION and PSMAfore 1,6."
"The VISION trial was the landmark phase III international trial that compared outcomes in 831 patients treated with 177Lu-PSMA-617 plus standard of care treatment versus standard of care treatment alone1. It found that median survival increased from 11.3 to 15.3 months with 177Lu-PSMA-617. Progression-free survival was an average of 8.7 months versus 3.4 months with standard of care therapy alone."
"The VISION trial was the landmark phase III international trial that compared outcomes in 831 patients treated with 177Lu-PSMA-617 plus standard of care treatment versus standard of care treatment alone1. It found that median survival increased from 11.3 to 15.3 months with 177Lu-PSMA-617. Progression-free survival was an average of 8.7 months versus 3.4 months with standard of care therapy alone."
"Lutetium-177 vipivotide tetraxetan, also known as 177Lu-PSMA-617 or its trade name Pluvicto (Novartis, USA), is a radioligand theranostic (i.e., both therapeutic and diagnostic) agent approved for the treatment of adult patients with treatment-resistant, advanced metastatic prostate cancer. The compound binds to cancer cells that express prostate-specific membrane antigen (PSMA), a biomarker associated with poor prognosis, and delivers beta-emitting radiation from lutetium 177, resulting in DNA damage and subsequent tumour cell death. Its clinical efficacy has been demonstrated in multiple prospective trials, including VISION and PSMAfore 1,6."
"Pre-treatment PET scan is performed using a PSMA-linked agent. 68Ga PSMA-11 (trade name Illuccix) was utilised in the VISION trial. Additional PSMA diagnostic agents include 18F piflufolastat (trade name Pylarify), 68Ga gozetotide (trade name Locametz), and 18F Flotufolastat (trade name Posluma). Patient selection requires demonstration of PSMA expression using approved PET imaging agents."
"History and manufacture "
"The VISION trial was the landmark phase III international trial that compared outcomes in 831 patients treated with 177Lu-PSMA-617 plus standard of care treatment versus standard of care treatment alone1. It found that median survival increased from 11.3 to 15.3 months with 177Lu-PSMA-617. Progression-free survival was an average of 8.7 months versus 3.4 months with standard of care therapy alone."
"Lutetium-177 vipivotide tetraxetan, also known as 177Lu-PSMA-617 or its trade name Pluvicto (Novartis, USA), is a radioligand theranostic (i.e., both therapeutic and diagnostic) agent approved for the treatment of adult patients with treatment-resistant, advanced metastatic prostate cancer. The compound binds to cancer cells that express prostate-specific membrane antigen (PSMA), a biomarker associated with poor prognosis, and delivers beta-emitting radiation from lutetium 177, resulting in DNA damage and subsequent tumour cell death. Its clinical efficacy has been demonstrated in multiple prospective trials, including VISION and PSMAfore 1,6."
"Lutetium-177 vipivotide tetraxetan, also known as 177Lu-PSMA-617 or its trade name Pluvicto (Novartis, USA), is a radioligand theranostic (i.e., both therapeutic and diagnostic) agent approved for the treatment of adult patients with treatment-resistant, advanced metastatic prostate cancer. The compound binds to cancer cells that express prostate-specific membrane antigen (PSMA), a biomarker associated with poor prognosis, and delivers beta-emitting radiation from lutetium 177, resulting in DNA damage and subsequent tumour cell death. Its clinical efficacy has been demonstrated in multiple prospective trials, including VISION and PSMAfore 1,6."
"Pluvicto was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2022."
"Pre-treatment PET scan is performed using a PSMA-linked agent. 68Ga PSMA-11 (trade name Illuccix) was utilised in the VISION trial. Additional PSMA diagnostic agents include 18F piflufolastat (trade name Pylarify), 68Ga gozetotide (trade name Locametz), and 18F Flotufolastat (trade name Posluma). Patient selection requires demonstration of PSMA expression using approved PET imaging agents."
Expected headings
"Characteristics"
"Use"
"Potential side effects"
"History and manufacture "
"External links"
"Pre-treatment PET scan is performed using a PSMA-linked agent. 68Ga PSMA-11 (trade name Illuccix) was utilised in the VISION trial. Additional PSMA diagnostic agents include 18F piflufolastat (trade name Pylarify), 68Ga gozetotide (trade name Locametz), and 18F Flotufolastat (trade name Posluma). Patient selection requires demonstration of PSMA expression using approved PET imaging agents."